Publicaciones en colaboración con investigadores/as de New York University Langone Medical Center (2)

2013

  1. Evidence available on the use of the selective β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder

    Actas Urologicas Espanolas

  2. Mirabegron for the treatment of overactive bladder: A prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

    International Journal of Clinical Practice, Vol. 67, Núm. 7, pp. 619-632